Longevity peptides occupy the widest gap between claim size and evidence quality anywhere in the peptide market. The claims are the largest possible — extended lifespan, telomere restoration, mitochondrial rejuvenation — and the supporting human evidence ranges from small, methodologically weak studies out of a single research lineage to none at all. This category also illustrates a recurring pattern: a legitimate, interesting research field (mitochondrial-derived peptides, immunomodulatory thymic peptides) feeding a consumer market that treats early findings as established therapy.

Sign in to read this Protocol Guide

The full Protocol Guide library is included with a free Peptide Data account. This guide is a 5-minute read.

Create free account

Already have an account? Sign in.